Ashvattha therapeutics presents positive interim phase 2 results for subcutaneous migaldendranib treatment for dme and wet-amd at 2025 maculart meeting

Monthly subcutaneous migaldendranib shows favorable safety with sustained efficacy through 24 weeks in patients with dme and wet-amd

AMD Ratings Summary

AMD Quant Ranking